SBIR Phase II: A novel 3D bioprinting system for rapid high-throughput tissue fabrication
SBIR II 期:一种用于快速高通量组织制造的新型 3D 生物打印系统
基本信息
- 批准号:2035835
- 负责人:
- 金额:$ 99.77万
- 依托单位:
- 依托单位国家:美国
- 项目类别:Cooperative Agreement
- 财政年份:2021
- 资助国家:美国
- 起止时间:2021-05-01 至 2023-04-30
- 项目状态:已结题
- 来源:
- 关键词:
项目摘要
The broader impact of this Small Business Innovation Research (SBIR) Phase II project is to provide a high-throughput biofabrication platform that can create physiologically relevant in vitro tissue models for diverse applications including drug testing, assay development, therapeutics, and biomedical research. The current drug development process is lengthy, inefficient, and expensive. It costs about $1.8 billion and takes 12-15 years to launch a single drug. Approximately 92% of the drugs that passed preclinical testing failed in subsequent human trials, highlighting the lack of adequate preclinical testing tools to generate predictive data. Failure to detect the drug-induced toxicity to the vital human organs in clinical trials often leads to market withdrawal of the drug after launch, which causes enormous financial losses to the drug manufacturer and also negative physical and mental effects for patients. The proposed technology will significantly improve drug safety, increase the efficiency and lower the cost of drug development by providing more reliable and clinically relevant drug testing results in a high-throughput fashion. This technology can also provide patient-specific tissues for critical biomedical research (e.g. disease modeling) and in vivo therapeutic applications, providing a viable solution to diseases without no cures or effective treatment yet.This Small Business Innovation Research (SBIR) Phase II project will support the development of a high-throughput biofabrication platform that is compatible with the high-throughput screening (HTS) systems widely used for drug screening and assay development. Currently, the key bottleneck for traditional microfabrication strategies and mainstream nozzle-based bioprinters is the lack of scalability and throughput to accommodate scalable manufacturing necessary in HTS systems. With the growing adoption of 3D biomimetic human tissue models in the pharmaceutical industry, there is a critical need for advanced manufacturing systems that enable rapid and streamlined tissue fabrication methods that are compatible with already established HTS platforms for preclinical toxicity testing of potential drug candidates. The proposed project will develop a parallel optical projection-based 3D bioprinting platform for direct manufacturing of 3D tissues within multiwell plates commonly used in the HTS systems. Implementation of the proposed 3D bioprinting system will permit subsequent in situ drug screening or assay testing directly within the wells and drastically improve biofabrication workflow efficiencies for the pharmaceutical industry and biomedical research community. This bioprinter will serve as a powerful instrument for the mass production of 3D tissue models at the industrial scale to advance drug discovery and assay development.This award reflects NSF's statutory mission and has been deemed worthy of support through evaluation using the Foundation's intellectual merit and broader impacts review criteria.
这个小型企业创新研究(SBIR)第二阶段项目的更广泛影响是提供一个高通量生物制品平台,可以为各种应用创建生理相关的体外组织模型,包括药物测试,检测开发,治疗和生物医学研究。目前的药物开发过程是漫长的,低效的,昂贵的。它耗资约18亿美元,需要12-15年才能推出一种药物。大约92%通过临床前测试的药物在随后的人体试验中失败,这突出表明缺乏足够的临床前测试工具来生成预测数据。在临床试验中未能检测到药物对人体重要器官的毒性,往往导致药物上市后退出市场,这给药物制造商造成了巨大的经济损失,也给患者带来了负面的身心影响。该技术将通过以高通量方式提供更可靠和临床相关的药物测试结果,显着提高药物安全性,提高效率并降低药物开发成本。这项技术还可以为关键的生物医学研究提供患者特异性组织(例如疾病建模)和体内治疗应用,提供一个可行的解决方案,以疾病没有治愈或有效的治疗尚未。这个小企业创新研究(SBIR)第二期项目将支持开发一个高通量生物制品平台,兼容高通量筛选(HTS)系统广泛用于药物筛选和检测开发。目前,传统的微制造策略和主流的基于生物打印机的关键瓶颈是缺乏可扩展性和吞吐量,以适应HTS系统中所需的可扩展制造。随着3D仿生人体组织模型在制药行业中的日益普及,迫切需要先进的制造系统,这些系统能够实现快速和简化的组织制造方法,这些方法与已经建立的HTS平台兼容,用于潜在候选药物的临床前毒性测试。拟议的项目将开发一个基于并行光学投影的3D生物打印平台,用于在HTS系统中常用的多孔板内直接制造3D组织。所提出的3D生物打印系统的实施将允许随后直接在威尔斯孔内进行原位药物筛选或测定测试,并大大提高制药行业和生物医学研究界的生物制造工作流程效率。这台生物打印机将作为一个强大的工具,用于在工业规模上大规模生产3D组织模型,以推进药物发现和检测开发。该奖项反映了NSF的法定使命,并通过使用基金会的知识价值和更广泛的影响审查标准进行评估,被认为值得支持。
项目成果
期刊论文数量(0)
专著数量(0)
科研奖励数量(0)
会议论文数量(0)
专利数量(0)
数据更新时间:{{ journalArticles.updateTime }}
{{
item.title }}
{{ item.translation_title }}
- DOI:
{{ item.doi }} - 发表时间:
{{ item.publish_year }} - 期刊:
- 影响因子:{{ item.factor }}
- 作者:
{{ item.authors }} - 通讯作者:
{{ item.author }}
数据更新时间:{{ journalArticles.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ monograph.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ sciAawards.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ conferencePapers.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ patent.updateTime }}
Wei Zhu其他文献
Improving the NV generation efficiency by electron irradiation
通过电子辐照提高NV产生效率
- DOI:
10.3788/col202018.080201 - 发表时间:
2020-07 - 期刊:
- 影响因子:3.5
- 作者:
Bowen Zhao;Yang Dong;Shaochun Zhang;Xiangdong Chen;Wei Zhu;Fangwen Sun - 通讯作者:
Fangwen Sun
Altered topological properties of the intrinsic functional brain network in patients with right-sided unilateral hearing loss caused by acoustic neuroma
听神经瘤引起的右侧单侧听力损失患者内在功能脑网络拓扑特性的改变
- DOI:
10.1007/s11682-022-00658-1 - 发表时间:
2022-04 - 期刊:
- 影响因子:3.2
- 作者:
Zhiyuan Fan;Zhen Fan;Tianming Qiu;Liuxun Hu;Yuan Shi;Yunman Xia;Xiaoyi Sun;Yingjun Liu;Sichen Li;Mingrui Xia;Wei Zhu - 通讯作者:
Wei Zhu
Pt/Ru/C nanocomposites for methanol electrooxidation: how Ru nanocrystals’ surface structure affects catalytic performance of deposited Pt particles
用于甲醇电氧化的 Pt/Ru/C 纳米复合材料:Ru 纳米晶体表面结构如何影响沉积 Pt 颗粒的催化性能
- DOI:
10.1039/c3qi00053b - 发表时间:
2014-01 - 期刊:
- 影响因子:7
- 作者:
Ze-Qiong Zhao;Guang-Xu Lan;Wei Zhu;Ya-Wen Zhang - 通讯作者:
Ya-Wen Zhang
Applying semantic web and big data techniques toconstruct a balance model referring to stakeholders of tourism intangiblecultural heritage
应用语义网和大数据技术构建旅游非物质文化遗产利益相关者平衡模型
- DOI:
- 发表时间:
2016 - 期刊:
- 影响因子:0
- 作者:
Meiyu Shi;Wei Zhu;Hongji Yang;Chen Li - 通讯作者:
Chen Li
H-Bert: Enhancing Chinese Pretrained Models with Attention to HowNet
- DOI:
- 发表时间:
2021 - 期刊:
- 影响因子:0
- 作者:
Wei Zhu - 通讯作者:
Wei Zhu
Wei Zhu的其他文献
{{
item.title }}
{{ item.translation_title }}
- DOI:
{{ item.doi }} - 发表时间:
{{ item.publish_year }} - 期刊:
- 影响因子:{{ item.factor }}
- 作者:
{{ item.authors }} - 通讯作者:
{{ item.author }}
{{ truncateString('Wei Zhu', 18)}}的其他基金
CDS&E: Robust Symmetry-Preserving Machine Learning: Theory and Application
CDS
- 批准号:
2244976 - 财政年份:2023
- 资助金额:
$ 99.77万 - 项目类别:
Continuing Grant
EAGER: CDS&E: Applied geometry and harmonic analysis in deep learning regularization: theory and applications
渴望:CDS
- 批准号:
2140982 - 财政年份:2021
- 资助金额:
$ 99.77万 - 项目类别:
Continuing Grant
CDS&E: Applied Geometry and Harmonic Analysis in Deep Learning Regularization: Theory and Applications
CDS
- 批准号:
2052525 - 财政年份:2020
- 资助金额:
$ 99.77万 - 项目类别:
Continuing Grant
CDS&E: Applied Geometry and Harmonic Analysis in Deep Learning Regularization: Theory and Applications
CDS
- 批准号:
1952992 - 财政年份:2020
- 资助金额:
$ 99.77万 - 项目类别:
Continuing Grant
SBIR Phase I: 3D Printing of Bisphenol A-free Polycarbonates for Customizable Cell/Tissue Culture Platforms
SBIR 第一阶段:用于可定制细胞/组织培养平台的不含双酚 A 的聚碳酸酯 3D 打印
- 批准号:
1819239 - 财政年份:2018
- 资助金额:
$ 99.77万 - 项目类别:
Standard Grant
Simulation of Liquid Crystal Elastomers
液晶弹性体的模拟
- 批准号:
1016504 - 财政年份:2010
- 资助金额:
$ 99.77万 - 项目类别:
Standard Grant
Almgren's multiple-valued functions and geometric measure theory
阿尔姆格伦的多值函数和几何测度论
- 批准号:
0905347 - 财政年份:2009
- 资助金额:
$ 99.77万 - 项目类别:
Standard Grant
相似国自然基金
Baryogenesis, Dark Matter and Nanohertz Gravitational Waves from a Dark
Supercooled Phase Transition
- 批准号:24ZR1429700
- 批准年份:2024
- 资助金额:0.0 万元
- 项目类别:省市级项目
ATLAS实验探测器Phase 2升级
- 批准号:11961141014
- 批准年份:2019
- 资助金额:3350 万元
- 项目类别:国际(地区)合作与交流项目
地幔含水相Phase E的温度压力稳定区域与晶体结构研究
- 批准号:41802035
- 批准年份:2018
- 资助金额:12.0 万元
- 项目类别:青年科学基金项目
基于数字增强干涉的Phase-OTDR高灵敏度定量测量技术研究
- 批准号:61675216
- 批准年份:2016
- 资助金额:60.0 万元
- 项目类别:面上项目
基于Phase-type分布的多状态系统可靠性模型研究
- 批准号:71501183
- 批准年份:2015
- 资助金额:17.4 万元
- 项目类别:青年科学基金项目
纳米(I-Phase+α-Mg)准共晶的临界半固态形成条件及生长机制
- 批准号:51201142
- 批准年份:2012
- 资助金额:25.0 万元
- 项目类别:青年科学基金项目
连续Phase-Type分布数据拟合方法及其应用研究
- 批准号:11101428
- 批准年份:2011
- 资助金额:23.0 万元
- 项目类别:青年科学基金项目
D-Phase准晶体的电子行为各向异性的研究
- 批准号:19374069
- 批准年份:1993
- 资助金额:6.4 万元
- 项目类别:面上项目
相似海外基金
SBIR Phase II: Innovative Two-Phase Cooling with Micro Closed Loop Pulsating Heat Pipes for High Power Density Electronics
SBIR 第二阶段:用于高功率密度电子产品的创新两相冷却微闭环脉动热管
- 批准号:
2321862 - 财政年份:2024
- 资助金额:
$ 99.77万 - 项目类别:
Cooperative Agreement
SBIR Phase II: Innovative Glass Inspection for Advanced Semiconductor Packaging
SBIR 第二阶段:先进半导体封装的创新玻璃检测
- 批准号:
2335175 - 财政年份:2024
- 资助金额:
$ 99.77万 - 项目类别:
Cooperative Agreement
SBIR Phase II: Intelligent Language Learning Environment
SBIR第二阶段:智能语言学习环境
- 批准号:
2335265 - 财政年份:2024
- 资助金额:
$ 99.77万 - 项目类别:
Cooperative Agreement
SBIR Phase II: FlashPCB Service Commercialization and AI Component Package Identification
SBIR第二阶段:FlashPCB服务商业化和AI组件封装识别
- 批准号:
2335464 - 财政年份:2024
- 资助金额:
$ 99.77万 - 项目类别:
Cooperative Agreement
SBIR Phase II: Thermally-optimized power amplifiers for next-generation telecommunication and radar
SBIR 第二阶段:用于下一代电信和雷达的热优化功率放大器
- 批准号:
2335504 - 财政年份:2024
- 资助金额:
$ 99.77万 - 项目类别:
Cooperative Agreement
SBIR Phase II: Sodium-Based Solid-State Batteries for Stationary Energy Storage
SBIR第二阶段:用于固定储能的钠基固态电池
- 批准号:
2331724 - 财政年份:2024
- 资助金额:
$ 99.77万 - 项目类别:
Cooperative Agreement
SBIR Phase II: A mesh-free, sling-free, minimally invasive treatment for stress urinary incontinence in women
SBIR II 期:无网、无吊带的微创治疗女性压力性尿失禁
- 批准号:
2233106 - 财政年份:2024
- 资助金额:
$ 99.77万 - 项目类别:
Cooperative Agreement
SBIR Phase II: Zero Trust Solution for Precision Medicine and Precision Health Data Exchanges
SBIR 第二阶段:精准医疗和精准健康数据交换的零信任解决方案
- 批准号:
2226026 - 财政年份:2024
- 资助金额:
$ 99.77万 - 项目类别:
Cooperative Agreement
SBIR Phase II: High-Performance Batteries to Decarbonize Heavy Duty Construction Equipment
SBIR 第二阶段:高性能电池使重型建筑设备脱碳
- 批准号:
2335320 - 财政年份:2024
- 资助金额:
$ 99.77万 - 项目类别:
Cooperative Agreement
SBIR Phase II: Technology for Stimulating the Herd Instinct of Livestock to Reduce Environmental Impact
SBIR第二阶段:刺激牲畜的群体本能以减少环境影响的技术
- 批准号:
2335554 - 财政年份:2024
- 资助金额:
$ 99.77万 - 项目类别:
Cooperative Agreement